We are pissed because we know the market for both acute respiratory disease and chronic respiratory management for Asthma and COPD given this will be for all age demographic (except COPD will only be adult) and this is even before COVID-19 screening. IMO, Pfizer will need to increase this to 25-30c for even a chance the top 20 holders will budge so will definitely be interesting what happen.
Big pharmacy like Pfizer can pay a "premium" to the current pps given the MC was so bloody low but the LT know the potential of RAP's products and the market want to see revenue with RAP finally starting to show this for ResAppDx-EU last quarter, hence the pps rose on those financial numbers even with a miniscule fraction of the market captured.
- Forums
- NZX - By Stock
- RAP
- What's a fair offer from Pfizer?
What's a fair offer from Pfizer?, page-26
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online